These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12176401)

  • 21. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P; Pescovitz MD; Hyatt D; Margreiter R
    Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
    Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
    [No Abstract]   [Full Text] [Related]  

  • 23. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical advances in therapies targeting the interleukin-2 receptor.
    Church AC
    QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
    [No Abstract]   [Full Text] [Related]  

  • 25. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract]   [Full Text] [Related]  

  • 26. Daclizumab in live donor renal transplantation.
    Iverson AJ; Vick SC; Sarnacki CT; Wright FH
    Transplant Proc; 2000 Jun; 32(4):790-2. PubMed ID: 10856587
    [No Abstract]   [Full Text] [Related]  

  • 27. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H; Bäckman L; Tufveson G; Tydén G
    Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract]   [Full Text] [Related]  

  • 28. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New immunosuppressive agents in pediatric renal transplantation.
    Ettenger RB
    Transplant Proc; 1998 Aug; 30(5):1956-8. PubMed ID: 9723350
    [No Abstract]   [Full Text] [Related]  

  • 30. Alemtuzumab in kidney-transplant recipients.
    Luan FL
    N Engl J Med; 2011 Aug; 365(7):671; author reply 671-2. PubMed ID: 21848469
    [No Abstract]   [Full Text] [Related]  

  • 31. New therapeutic monoclonal antibodies target kidney transplant rejection and cancer.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(3):379-80. PubMed ID: 9654869
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
    Baczkowska T; Kukula K; Nowacka-Cieciura E; Cieciura T; Lewandowska D; Ciecierski R; Grochowiecki T; Rowinski W; Szmidt J; Durlik M; Lao M
    Transplant Proc; 2002 Mar; 34(2):551-2. PubMed ID: 12009620
    [No Abstract]   [Full Text] [Related]  

  • 33. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B; Thervet E
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
    González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
    Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody approved for renal transplants.
    Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
    [No Abstract]   [Full Text] [Related]  

  • 37. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
    Madsen M; Svendsen UG
    Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
    Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interleukin-2 receptor blockers in renal transplantation].
    Basić-Jukić N; Bubić-Filipi L; Danić A; Pasini J; Kes P
    Acta Med Croatica; 2004; 58(5):395-9. PubMed ID: 15756806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.